

Appendix Table. Antimicrobial resistance profile of PVL-positive CA-MRSA clone*

<i>agr</i> type	ST	N (%)	Antimicrobial resistance profile	N (%)	Countries of detection (N)
<i>agr1</i>		46 (9.8)			
	ST8	25 (54.3)	P, OX P, OX, K P, OX, TE P, OX, K, E P, OX, E, OFL P, OX, K, TE P, OX, K, E, OFL P, OX, K, E, TE P, OX, K, E, TE, OFL P, OX, K, E, L, TE, MU P, OX, K, E, L, OFL, MU	8 (32.0) 1 (4.0) 3 (12.0) 6 (24.0) 1 (4.0) 1 (4.0) 1 (4.0) 1 (4.0) 1 (4.0) 1 (4.0) 1 (4.0) 1 (4.0)	Spain (2), Switzerland (2), United States (3), France (1) Switzerland (1) Spain (1), the Netherlands (2) France (1), the Netherlands (2), US (2) France (1) French Polynesia (1) US (1) Switzerland (1) Switzerland (1) The Netherlands (1) United States (1) France (2), the Netherlands (2), Singapore (1) United States (1) France (1) The Netherlands (2) Germany (1) Singapore (1)
	ST59	7 (15.2)	P, OX, K, E, L, TE P, OX	5 (71.4) 1 (14.3)	France (2), the Netherlands (2), Singapore (1) United States (1)
	ST22	3 (6.5)	P, OX, K, T, G, E, L, TE P, OX, K, T, G	1 (14.3) 2 (66.7)	France (1) The Netherlands (2)
	ST766	1 (2.2)	P, OX, FU	1 (33.3)	Germany (1)
	ST766	1 (2.2)	P, OX, K, T, G, E, TE, OFL	1 (100.0)	Singapore (1)
	ST377	10 (21.7)	P, OX, K, T, G	10 (100.0)	The Netherlands (1), France (1), Greece (5), Switzerland (2), Australia (1)
<i>agr2</i>		9 (1.9)			
	ST5	9 (100.0)	P, OX, TE, FU P, OX, K, T, E, L, TE	8 (88.9) 1 (11.1)	France (3), Switzerland (5) Algeria (1)
<i>agr3</i>		414 (88.3)			
	ST80	357 (83.2)	P, OX, K P, OX, K, E P, OX, K, FU P, OX, K, TE P, OX, K, E, FU P, OX, K, E, L P, OX, K, E, Rif P, OX, K, OFL, FU P, OX, K, TE, FU P, OX, K, T, G P, OX, K, E, L, FU P, OX, K, E, TE, OFL P, OX, K, E, TE, FU P, OX, K, E, L, TE, FU P, OX, K, T, E, L, TE P, OX, K, T, G, OFL, FU P, OX, K, T, G, TE, FU P, OX, K, E, L, TE, OFL, FU P, OX, K, T, G, E, OFL, FU P, OX, K, T, E, L, OFL, FU P, OX, K, T, G, E, TE, FU P, OX, K, T, G, OFL, FU, Rif P, OX, K, T, G, TE, FU, Rif P, OX, K, T, E, L, PRI, OFL, FU P, OX, K, T, G, E, L, PRI, OFL, FU	25 (7.0) 12 (3.4) 19 (5.3) 6 (1.7) 8 (2.2) 1 (0.3) 1 (0.3) 1 (0.3) 205 (57.4) 1 (0.3) 1 (0.3) 1 (0.3) 59 (16.5) 2 (0.6) 1 (0.3) 2 (0.6) 1 (0.3) 2 (0.6) 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3) 2 (0.6) 1 (0.3) 2 (0.6) 1 (0.3) 1 (0.3)	Algeria (9), France (13), Greece (1), Switzerland (2) Algeria (5), France (6), Switzerland (1) Algeria (4), France (13), Switzerland (2) Algeria (1), France (5) France (1) Algeria (1) Algeria (1) Algeria (27), Belgium (1), France (147), Germany (1), Greece (3), The Netherlands (2), Slovenia (3), Switzerland (20), Singapore (1) France (1) France (1) France (1) Algeria (5), France (48), Romania (1), Switzerland (5) France (2) Algeria (1) Algeria (2) Algeria (1) Algeria (2) Algeria (1) Algeria (1) France (1) Algeria (2) Algeria (1) Algeria (2) Algeria (1) Algeria (2) Algeria (1) Algeria (1)
	ST30	20 (4.8)	P, OX P, OX, K, T P, OX, K, T, G, E, L P, OX, K, T, G, E, TE	18 (90.0) 1 (5.0) 1 (5.0) 1 (100.0)	The Netherlands (1), Australia (8), Japan (1), New-Zealand (4), Western Samoa (1), Switzerland (2), Singapore (1) French Polynesia (1) China (1) The Netherlands (1)
	ST37	1 (0.2)	P, OX	3 (75.0)	Australia (3)
	ST93	4 (100.0)	P, OX, E P, OX	1 (25.0) 17 (53.1)	Australia (1) US (17)
	ST1	32 (7.7)	P, OX, E P, OX, TE P, OX, K, T, G	10 (31.2) 4 (12.5) 1 (3.1)	US (9), France (1) United States (4) Singapore (1)

Publisher: CDC; Journal: Emerging Infectious Diseases
Article Type: Research; Volume: 13; Issue: 4; Year: 2007; Article ID: 06-1316
DOI: 10.3201/eid1304.061316; TOC Head: Research

*Panton-Valentine leukocidin (PVL); CA-MRSA, community-acquired methicillin-resistant *Staphylococcus aureus*; penicillin (P), oxacillin, (OX), kanamycin (K), tobramycin (T), gentamicin (G), erythromycin (E), lincomycin (L), tetracycline (TE), pristinamycin (PRI), ofloxacin (OFL), fusidic acid (FU), rifampycin (Rif).